Sort by
Items per page

Send to

Choose Destination

Best matches for Danø K[au]:

Plasminogen activation and cancer. Danø K et al. Thromb Haemost. (2005)

Healing hormones. Rømer J et al. Nat Med. (1997)

Plasminogen activators, tissue degradation, and cancer. Danø K et al. Adv Cancer Res. (1985)

Search results

Items: 1 to 50 of 227


Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry.

Laerum OD, Ovrebo K, Skarstein A, Christensen IJ, Alpízar-Alpízar W, Helgeland L, Danø K, Nielsen BS, Illemann M.

Int J Cancer. 2012 Aug 1;131(3):558-69. doi: 10.1002/ijc.26382. Epub 2011 Oct 20.


Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis.

Almasi CE, Christensen IJ, Høyer-Hansen G, Danø K, Pappot H, Dienemann H, Muley T.

Lung Cancer. 2011 Dec;74(3):510-5. doi: 10.1016/j.lungcan.2011.05.008. Epub 2011 Jun 2.


Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.

Almasi CE, Brasso K, Iversen P, Pappot H, Høyer-Hansen G, Danø K, Christensen IJ.

Prostate. 2011 Jun 1;71(8):899-907. doi: 10.1002/pros.21306. Epub 2010 Nov 17.


Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.

Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, Danø K, Nielsen BS.

Int J Cancer. 2009 Apr 15;124(8):1860-70. doi: 10.1002/ijc.24166.


Crohn's disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons.

Laerum OD, Illemann M, Skarstein A, Helgeland L, Ovrebø K, Danø K, Nielsen BS.

Am J Gastroenterol. 2008 Sep;103(9):2350-8. doi: 10.1111/j.1572-0241.2008.01930.x.


Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model.

Almholt K, Juncker-Jensen A, Laerum OD, Danø K, Johnsen M, Lund LR, Rømer J.

Mol Cancer Ther. 2008 Sep;7(9):2758-67. doi: 10.1158/1535-7163.MCT-08-0251.


The plasminogen fibrinolytic pathway is required for hematopoietic regeneration.

Heissig B, Lund LR, Akiyama H, Ohki M, Morita Y, Rømer J, Nakauchi H, Okumura K, Ogawa H, Werb Z, Danø K, Hattori K.

Cell Stem Cell. 2007 Dec 13;1(6):658-70. doi: 10.1016/j.stem.2007.10.012. Erratum in: Cell Stem Cell. 2008 Jul 3;3(1):120.


A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.

Hillig T, Engelholm LH, Ingvarsen S, Madsen DH, Gårdsvoll H, Larsen JK, Ploug M, Danø K, Kjøller L, Behrendt N.

J Biol Chem. 2008 May 30;283(22):15217-23. doi: 10.1074/jbc.C700214200. Epub 2008 Mar 24.


Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.

Pass J, Jögi A, Lund IK, Rønø B, Rasch MG, Gårdsvoll H, Lund LR, Ploug M, Rømer J, Danø K, Høyer-Hansen G.

Thromb Haemost. 2007 Jun;97(6):1013-22.


Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.

Lund LR, Green KA, Stoop AA, Ploug M, Almholt K, Lilla J, Nielsen BS, Christensen IJ, Craik CS, Werb Z, Danø K, Rømer J.

EMBO J. 2006 Jun 21;25(12):2686-97. Epub 2006 Jun 8.


MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases.

Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR, Danø K, Nielsen BS.

Mol Cancer Res. 2006 May;4(5):293-302.


Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.

Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brünner N, Danø K, Høyer-Hansen G, Lilja H.

Clin Chem. 2006 May;52(5):838-44. Epub 2006 Mar 16.


Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.

Almasi CE, Høyer-Hansen G, Christensen IJ, Danø K, Pappot H.

Lung Cancer. 2005 Jun;48(3):349-55.


Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.

Llinas P, Le Du MH, Gårdsvoll H, Danø K, Ploug M, Gilquin B, Stura EA, Ménez A.

EMBO J. 2005 May 4;24(9):1655-63. Epub 2005 Apr 7.


Plasminogen activation and cancer.

Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Rømer J.

Thromb Haemost. 2005 Apr;93(4):676-81. Review.


Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas.

Pedersen TX, Pennington CJ, Almholt K, Christensen IJ, Nielsen BS, Edwards DR, Rømer J, Danø K, Johnsen M.

Carcinogenesis. 2005 Jul;26(7):1233-40. Epub 2005 Mar 10.


Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.

Maillard C, Jost M, Rømer MU, Brunner N, Houard X, Lejeune A, Munaut C, Bajou K, Melen L, Dano K, Carmeliet P, Fusenig NE, Foidart JM, Noel A.

Neoplasia. 2005 Jan;7(1):57-66.


Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry.

Jørgensen TJ, Gårdsvoll H, Danø K, Roepstorff P, Ploug M.

Biochemistry. 2004 Nov 30;43(47):15044-57.


Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.

Usher PA, Thomsen OF, Iversen P, Johnsen M, Brünner N, Høyer-Hansen G, Andreasen P, Danø K, Nielsen BS.

Int J Cancer. 2005 Mar 1;113(6):870-80.


Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.

Almholt K, Lund LR, Rygaard J, Nielsen BS, Danø K, Rømer J, Johnsen M.

Int J Cancer. 2005 Feb 10;113(4):525-32.


Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.

Piironen T, Laursen B, Pass J, List K, Gårdsvoll H, Ploug M, Danø K, Høyer-Hansen G.

Clin Chem. 2004 Nov;50(11):2059-68. Epub 2004 Sep 2.


Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1.

Illemann M, Hansen U, Nielsen HJ, Andreasen PA, Høyer-Hansen G, Lund LR, Danø K, Nielsen BS.

Am J Clin Pathol. 2004 Aug;122(2):256-65.


Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor.

Hansen LV, Gårdsvoll H, Nielsen BS, Lund LR, Danø K, Jensen ON, Ploug M.

Biochem J. 2004 Jun 15;380(Pt 3):845-57.


uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV.

Kjøller L, Engelholm LH, Høyer-Hansen M, Danø K, Bugge TH, Behrendt N.

Exp Cell Res. 2004 Feb 1;293(1):106-16.


Diverse microbial communities inhabiting ferromanganese deposits in Lechuguilla and Spider Caves.

Northup DE, Barns SM, Yu LE, Spilde MN, Schelble RT, Dano KE, Crossey LJ, Connolly CA, Boston PJ, Natvig DO, Dahm CN.

Environ Microbiol. 2003 Nov;5(11):1071-86.


A functional overlap of plasminogen and MMPs regulates vascularization during placental development.

Solberg H, Rinkenberger J, Danø K, Werb Z, Lund LR.

Development. 2003 Sep;130(18):4439-50.


Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.

Almholt K, Nielsen BS, Frandsen TL, Brünner N, Danø K, Johnsen M.

Oncogene. 2003 Jul 10;22(28):4389-97.


Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma.

Pedersen TX, Leethanakul C, Patel V, Mitola D, Lund LR, Danø K, Johnsen M, Gutkind JS, Bugge TH.

Oncogene. 2003 Jun 19;22(25):3964-76.


uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion.

Engelholm LH, List K, Netzel-Arnett S, Cukierman E, Mitola DJ, Aaronson H, Kjøller L, Larsen JK, Yamada KM, Strickland DK, Holmbeck K, Danø K, Birkedal-Hansen H, Behrendt N, Bugge TH.

J Cell Biol. 2003 Mar 31;160(7):1009-15.


Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.

Ploug M, Gårdsvoll H, Jørgensen TJ, Lønborg Hansen L, Danø K.

Biochem Soc Trans. 2002 Apr;30(2):177-83. Review.


Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer.

Nielsen BS, Sehested M, Duun S, Rank F, Timshel S, Rygaard J, Johnsen M, Danø K.

Lab Invest. 2001 Nov;81(11):1485-501.


The urokinase plasminogen activator receptor-associated protein/endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis.

Engelholm LH, Nielsen BS, Netzel-Arnett S, Solberg H, Chen XD, Lopez Garcia JM, Lopez-Otin C, Young MF, Birkedal-Hansen H, Danø K, Lund LR, Behrendt N, Bugge TH.

Lab Invest. 2001 Oct;81(10):1403-14.


Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.

Nielsen BS, Rank F, López JM, Balbin M, Vizoso F, Lund LR, Danø K, López-Otín C.

Cancer Res. 2001 Oct 1;61(19):7091-100.


Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.

Ploug M, Østergaard S, Gårdsvoll H, Kovalski K, Holst-Hansen C, Holm A, Ossowski L, Danø K.

Biochemistry. 2001 Oct 9;40(40):12157-68.


Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.

Høyer-Hansen G, Pessara U, Holm A, Pass J, Weidle U, Danø K, Behrendt N.

Biochem J. 2001 Sep 15;358(Pt 3):673-9.


[New basis for development of anticancer drugs].

Danø K.

Ugeskr Laeger. 2001 Jul 2;163(27):3759-62. Danish.


The urokinase receptor associated protein (uPARAP/endo180): a novel internalization receptor connected to the plasminogen activation system.

Engelholm LH, Nielsen BS, Danø K, Behrendt N.

Trends Cardiovasc Med. 2001 Jan;11(1):7-13. Review.


A precise and efficient stereological method for determining murine lung metastasis volumes.

Nielsen BS, Lund LR, Christensen IJ, Johnsen M, Usher PA, Wulf-Andersen L, Frandsen TL, Danø K, Gundersen HJ.

Am J Pathol. 2001 Jun;158(6):1997-2003.


The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.

Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noël A.

J Cell Biol. 2001 Feb 19;152(4):777-84.


Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.

Rømer J, Pyke C, Lund LR, Ralfkiaer E, Danø K.

J Invest Dermatol. 2001 Mar;116(3):353-8.


The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.

Pedersen AN, Christensen IJ, Stephens RW, Briand P, Mouridsen HT, Danø K, Brünner N.

Cancer Res. 2000 Dec 15;60(24):6927-34.


Lactational competence and involution of the mouse mammary gland require plasminogen.

Lund LR, Bjørn SF, Sternlicht MD, Nielsen BS, Solberg H, Usher PA, Osterby R, Christensen IJ, Stephens RW, Bugge TH, Danø K, Werb Z.

Development. 2000 Oct;127(20):4481-92.


Loss of ELISA specificity due to biotinylation of monoclonal antibodies.

Høyer-Hansen G, Hamers MJ, Pedersen AN, Nielsen HJ, Brünner N, Danø K, Stephens RW.

J Immunol Methods. 2000 Feb 21;235(1-2):91-9.


Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization.

Gårdsvoll H, Solberg H, Dano K, Høyer-Hansen G.

J Immunol Methods. 2000 Feb 3;234(1-2):107-16.


Supplemental Content

Support Center